Status:
RECRUITING
Tumor Vaccines for Solid Tumors
Lead Sponsor:
Huashan Hospital
Conditions:
Glioma
Solid Tumor
Eligibility:
All Genders
Brief Summary
Glioma is the most common primary malignant intracranial tumor, characterized by limited clinical treatment options and extremely poor prognosis. There is an urgent need for the development of new tec...
Eligibility Criteria
Inclusion
- The patients with glioma patients/non-tumor patients (hemorrhagic stroke, ischemic stroke, and traumatic brain injury) in the Department of Neurosurgery of Huashan Hospital Affiliated to Fudan University who meet the following three conditions can be enrolled:
- They were no age limit, male and female;
- The pathological results of frozen section during operation were gliomas or non-tumor;
- Tissue (6 mm \* 6 mm) can be used for cell sorting on the basis of not affecting clinical routine diagnosis;
- Sign informed consent.
Exclusion
- Patients who meet any of the following criteria will not be included in this study:
- Participants in other clinical trials;
- Pregnant women.
Key Trial Info
Start Date :
October 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 1 2027
Estimated Enrollment :
340 Patients enrolled
Trial Details
Trial ID
NCT06102837
Start Date
October 1 2023
End Date
October 1 2027
Last Update
October 26 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Huashan Hospital, Fudan University
Shanghai, Shanghai Municipality, China, 200040